New drug duo aims to control rare lymphoma without chemotherapy

This study tests whether combining zanubrutinib (a targeted pill) with rituximab (an antibody infusion) can shrink or control MALT lymphoma, a slow-growing cancer of the lymph nodes and organs. About 42 adults with newly diagnosed advanced disease or lymphoma that returned after local treatment will receive the combination. The goal is to see how many patients achieve complete remission and how long the benefit lasts.